Researchers at the University of Warwick to benefit from £18M investment in world-class frontier bioscience

05 Oct 2023 | Network Updates | Update from University of Warwick
These updates are republished press releases and communications from members of the Science|Business Network

Researchers at The University of Warwick are among four world-class teams receiving a share of £18 million to pursue transformational bioscience research programmes.

Funded by the Biotechnology and Biological Sciences Research Council’s (BBSRC), the four teams will tackle bold challenges at the frontiers of bioscience, combining world-class ideas, people and transformative technologies with the aim of uncovering fundamental rules of life.

The team from the University of Warwick’s School of Life Sciences will investigate the bacterial cell wall – which could help to develop new classes of antibiotics, tackling the global challenge of antibiotic resistance.

Cell walls are essential for the survival of most bacteria and they dictate bacteria shape. They mostly made of a compound called peptidoglycan which binds together to form new wall material by a combination of proteins known as the ‘elongasome’. Remarkably, we know very little about how this important protein complex functions at a molecular level. This represents a key knowledge-gap in our understanding of bacterial physiology.

Through a coalescence of microbial biochemistry, biophysics, and chemical biology, the team leading this project aim to provide new insight into how the bacterial cell wall is formed. They will deploy structural analyses in tandem with molecular dynamics simulations to determine the basis of elongasome function and regulation from the atomic through to the macromolecular scale. This will lead to a significant advance in our understanding of how bacterial cell walls form.

Further, this project may lay the foundations for development of fundamentally new classes of antibiotics that inhibit the elongasome machinery.

This project is a collaboration between University of Warwick and Queen’s University Belfast. It is led by Professor David Roper in collaboration with Stephen Cochrane, Séamus Holden and Phillip Stansfeld.

Professor David Roper, University of Warwick, said“This is a fantastic opportunity to apply an integrated, interdisciplinary approach to a understand how bacteria make and control their cell walls that may provide us with the knowledge and tools to develop new antibiotics. The provision of this five-year funding means we can all work together in a way that is not normally possible”.

The investment from the BBSRC’s strategic Longer Larger grants programme (sLoLa) aims to catalyse and convene the critical mass of research effort needed to address significant fundamental questions in bioscience.

Professor Guy Poppy, Interim Executive Chair at BBSRC, added: “The latest investment by BBSRC’s sLoLa award programme represents a pivotal step in advancing frontier bioscience research.

“These four world-class teams are poised to unravel the fundamental rules of life, employing interdisciplinary approaches to tackle bold challenges at the forefront of bioscience.

“By fostering collaboration and innovation, we aim to catalyse ground-breaking discoveries with far-reaching implications for agriculture, health, biotechnology, the green economy and beyond.”

This article was first published on 29 September by University of Warwick.

Never miss an update from Science|Business:   Newsletter sign-up